Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAF265 oral dose-escalation study in advanced or metastatic melanoma
NL-OMON33745Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of RAF265 in melanoma (4 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Safety profile and 4 more. Planned start Jun 2009; status: not yet recruiting.
02
Drugs
RAF265
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON33745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33745.